Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.84 |
| ▸ | NOS2 | P35228 | 9/20 | 0.83 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.82 |
| ▸ | USP7 | Q93009 | 2/20 | 0.82 |
| ▸ | USP2 | O75604 | 1/20 | 0.82 |
| ▸ | STAT3 | P40763 | 1/20 | 0.82 |
| ▸ | CCR6 | P51684 | 1/20 | 0.71 |
| ▸ | RORC | P51449 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15021390 | 1.00 | MBOAT4 (0.84) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL22428638 | 1.00 | MBOAT4 (0.84) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL7717247 | 1.00 | MBOAT4 (0.84) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL91616 | 1.00 | MBOAT4 (0.84) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL13499871 | 1.00 | MBOAT4 (0.84) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL13569167 | 0.93 | MBOAT4 (0.84) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL4192575 | 0.93 | MBOAT4 (0.84) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL13569164 | 0.93 | MBOAT4 (0.84) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL3489259 | 0.93 | MBOAT4 (0.84) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL24450687 | 0.93 | MBOAT4 (0.88) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024127022-A1 | HETEROCYCLIC COMPOUNDS TARGETING THE NUDT5 PROTEIN | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-06-20 | — | — | WO | disclosed |
| US-20230255982-A1 | METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF | Reata Pharmaceuticals Holdings, LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20170333450-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-ASSOCIATED COGNITIVE DYSFUNCTION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333450-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-ASSOCIATED COGNITIVE DYSFUNCTION | CD14, CCL2, CCR5 | MBOAT4 3418/4885NOS2 14/4885KEAP1 107/4885 |
| US-20230255982-A1 | METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF | CYP17A1, HSD11B2, HSD11B1 | MBOAT4 619/4885NOS2 471/4885KEAP1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.